ProPhase Net Working Capital from 2010 to 2026

PRPH Stock  USD 0.16  0.01  5.88%   
ProPhase Labs' Net Working Capital is decreasing with slightly volatile movements from year to year. Net Working Capital is estimated to finish at about -1.6 M this year. For the period between 2010 and 2026, ProPhase Labs, Net Working Capital quarterly trend regression had median of  27,847,000 and r-value of (0.47). View All Fundamentals
 
Net Working Capital  
First Reported
2020-03-31
Previous Quarter
-1.1 M
Current Value
-47.5 M
Quarterly Volatility
24.5 M
 
Covid
 
Interest Hikes
Check ProPhase Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProPhase Labs' main balance sheet or income statement drivers, such as Interest Expense of 4 M, Selling General Administrative of 32.4 M or Total Revenue of 7.4 M, as well as many indicators such as Price To Sales Ratio of 2.33, Dividend Yield of 0.13 or PTB Ratio of 2.15. ProPhase financial statements analysis is a perfect complement when working with ProPhase Labs Valuation or Volatility modules.
  
Build AI portfolio with ProPhase Stock
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.
The Net Working Capital trend for ProPhase Labs offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether ProPhase Labs is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest ProPhase Labs' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of ProPhase Labs over the last few years. It is ProPhase Labs' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProPhase Labs' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

ProPhase Net Working Capital Regression Statistics

Arithmetic Mean21,635,940
Coefficient Of Variation67.75
Mean Deviation12,007,019
Median27,847,000
Standard Deviation14,657,830
Sample Variance214.9T
Range47.5M
R-Value(0.47)
Mean Square Error178.2T
R-Squared0.22
Significance0.06
Slope(1,368,528)
Total Sum of Squares3437.6T

ProPhase Net Working Capital History

2026-1.6 M
2025-1.7 M
2024-1.5 M
202326.7 M
202244.8 M
202145.8 M
20209.6 M

About ProPhase Labs Financial Statements

Investors use fundamental indicators, such as ProPhase Labs' Net Working Capital, to determine how well the company is positioned to perform in the future. Although ProPhase Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Working Capital-1.7 M-1.6 M

Currently Active Assets on Macroaxis

When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is there potential for Pharmaceuticals market expansion? Will ProPhase introduce new products? Factors like these will boost the valuation of ProPhase Labs. Anticipated expansion of ProPhase directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.95)
Earnings Share
(19.80)
Revenue Per Share
1.402
Quarterly Revenue Growth
(0.38)
Return On Assets
(0.23)
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between ProPhase Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProPhase Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, ProPhase Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.